|
Forecast Period
|
2026-2030
|
|
Market Size (2024)
|
USD 1.16 Billion
|
|
Market Size (2030)
|
USD 3.04 Billion
|
|
CAGR (2025-2030)
|
17.39%
|
|
Fastest Growing Segment
|
Synthetic Biology
|
|
Largest Market
|
North America
|
Market Overview
The Global Multiomics Services Market was
valued at USD 1.16 Billion in 2024 and is expected to reach USD 3.04 Billion by
2030 with a CAGR of 17.39%. The Global Multiomics Services Market is
experiencing significant expansion as healthcare systems, research
institutions, and pharmaceutical companies increasingly adopt integrated omics
approaches to address the growing need for precision medicine and personalized
healthcare solutions. Multiomics services, which combine genomics,
transcriptomics, proteomics, metabolomics, and epigenomics, allow for a
comprehensive understanding of biological systems and disease mechanisms. These
approaches are becoming critical in drug discovery, biomarker identification,
and the development of targeted therapies. The growing prevalence of chronic
and genetic diseases, rising demand for advanced diagnostic solutions, and
strong collaborations between academic institutions and industry players are
pushing the adoption of multiomics services. With technological advancements in
next-generation sequencing, mass spectrometry, and bioinformatics, the
efficiency and scalability of these services have improved significantly,
making them more accessible across multiple end-user sectors.
The growth of the multiomics services
market is driven by a combination of factors, including the rising focus on
precision healthcare, the need for early disease detection, and the increasing
use of omics data in clinical decision-making. Pharmaceutical and biotechnology
companies are leveraging multiomics to streamline drug development pipelines,
reduce attrition rates, and enhance the success of clinical trials. The
integration of advanced bioinformatics platforms and artificial intelligence is
enabling more accurate data interpretation, leading to breakthroughs in disease
profiling and patient stratification. Strategic collaborations and funding
support from governments and private investors are accelerating innovation and
expanding the service landscape. In addition, the rising adoption of companion
diagnostics, driven by regulatory approval for targeted therapies, is further
creating demand for multiomics services, as these tools play a central role in
identifying the right patient groups for specific treatments.
Despite the promising growth prospects,
the market faces challenges that could impact its pace of expansion. High costs
associated with multiomics studies, particularly when integrating multiple
datasets, pose affordability concerns for smaller institutions and emerging
economies. Data complexity and interoperability issues remain significant
hurdles, as large-scale omics studies generate massive datasets requiring
sophisticated analytical tools and skilled professionals for interpretation.
Concerns over data privacy and the lack of standardized protocols across
laboratories further complicate widespread adoption. Nonetheless, these
challenges also create opportunities for innovation, as companies are
developing more cost-efficient platforms, cloud-based data solutions, and
integrated software to simplify analysis and improve scalability. With
continuous advancements in bioinformatics, artificial intelligence, and
automation, the market is expected to overcome many of these barriers, paving
the way for widespread adoption of multiomics in healthcare and research over
the coming years.
Key Market Drivers
Growing
Research in Complex Diseases
Rising research into complex diseases
continues to drive strong momentum in the Global Multiomics Services Market.
Conditions such as cancer, neurodegenerative diseases, cardiovascular
disorders, autoimmune illnesses, and rare genetic syndromes involve multifaceted
biological pathways that cannot be fully described by single-layer analyses. By
integrating genomics, transcriptomics, proteomics, epigenomics, and
metabolomics, multiomics enables an in-depth view of disease mechanisms,
facilitating discovery of novel biomarkers and therapeutic targets. For
example, in September 2023 the U.S. National Institutes of Health announced a
USD 50.3 million investment over five years to establish the Multi-Omics for
Health and Disease Consortium, funding diverse disease studies and scalable
workflows for integrating complex datasets. This type of strategic
support underscores how critical multiomics has become in tackling intricate
health challenges.
Pharmaceutical and biotech firms are
turning increasingly to multiomics strategies to bolster drug development
efforts in complex disease areas. Heterogeneous patient responses and disease
subtypes demand precision; multiomics data helps stratify patient groups,
predict outcomes, and optimize clinical trial design. This approach reduces
failure rates and accelerates time-to-market for new therapies. Integration
with advanced bioinformatics and AI accelerates interpretation of massive
datasets, empowering accelerated insights in oncology, neurological disorders,
chronic and metabolic conditions. Strong interest among healthcare providers
and research organizations in these capabilities continues to bolster demand
for multiomics services.
Academic institutions, public–private
partnerships, and government agencies worldwide are pouring resources into
large-scale multiomics projects focused on elucidating complex disease biology.
Availability of funding and infrastructure from agencies such as the NIH helps
drive cross-disciplinary collaborations. As healthcare shifts toward
predictive, preventive, and personalized paradigms, multiomics research is
increasingly central to that transition. The combination of governmental
funding, technological advances in high-throughput platforms, and growing
pharmaceutical and academic demand ensures that the study of complex diseases
will remain one of the most significant long-term drivers for the multiomics
services market.
Increased
Investments and Collaborations
A significant driver for the Global Multiomics
Services Market is the surge in strategic investments and collaborative
initiatives that are fueling both technological innovation and widespread
adoption. Multiomics research relies on advanced sequencing instruments,
high-resolution mass spectrometers, single-cell platforms, and powerful
bioinformatics infrastructure, all of which require substantial capital. To
address these resource-intensive needs, pharmaceutical companies, biotechnology
firms, and academic institutions are frequently partnering with specialized
multiomics service providers, sharing both risk and expertise across joint
ventures to make high-end services more accessible.
Government funding is playing an equally pivotal role.
In 2024, NIH-sponsored academic research grants generated an impressive
USD 94.6 billion in economic activity across the United States and supported
over 400,000 jobs, yielding a USD 2.56 return for every USD 1 invested. This
multiplier effect illustrates not only the broader social and economic benefits
but also reinforces investors’ confidence in directing funds toward multiomics
research infrastructure and platforms. Specific to omics, NIH established
the Multi-Omics for Health and Disease Consortium in 2023, committing USD 50.3
million over five years to advance integrated omics studies in human health.
These significant federal commitments reduce the
financial burden on individual stakeholders and encourage investment in
omics-enabled tools and analytics. Public–private partnerships bolster
innovation by combining cutting-edge academic research with commercial product
development and scalability. As a result, integrated multiomics pipelines,
cloud-based data solutions, and AI-driven analytic tools are growing more
refined and widely accessible. The infusion of capital, driven by both public
grant funding and private collaboration, is creating a conducive environment
for rapid progress, strengthening the market’s growth trajectory and
reinforcing multiomics as a cornerstone of next-generation precision medicine
and healthcare innovation.
Expansion
of Drug Discovery and Development
The expansion of drug discovery and development is
accelerating the Global Multiomics Services Market, driven by the demand for
more precise biomarker identification and targeted therapies. Multiomics, encompassing
genomics, epigenomics, transcriptomics, proteomics, metabolomics enables deep
insight into disease mechanisms, allowing researchers to uncover novel
therapeutic targets, stratify patient populations more effectively, and reduce
clinical trial attrition. Pharmaceutical and biotech companies are increasingly
using integrated omics approaches to optimize both preclinical screening and
patient selection in clinical phases, thereby improving success rates and
reducing development timelines.
Government investment validates this trend: The
U.S. National Institutes of Health (NIH) allocated approximately USD 50.3
million over five years (with USD 11 million in the first year) to establish
the Multi-Omics for Health and Disease Consortium. This program
supports multiomics research across conditions such as fatty liver disease,
liver cancer, asthma, chronic kidney disease, and preeclampsia, with a focus on
diverse and underrepresented populations. Such strategic funding highlights
institutional confidence in multiomics as a foundational tool for disease
profiling and therapeutic innovation. Multiomics capabilities not only enable
drug repurposing by revealing new indications through complex biological
insights, but they also streamline regulatory submission packages by providing
robust molecular evidence.
Collaborations between service providers, academic
institutions, and pharmaceutical companies are increasingly common, often
backed by government incentives and translational funding. Regulatory bodies
are more receptive to biomarker-driven drug approval pathways, further enabling
multiomics adoption. As drug pipelines shift toward oncology, rare diseases,
and immunology, the reliance on multiomics for mechanism elucidation, safety
profiling, and efficacy prediction is becoming transformative. Use of real-world
data, artificial intelligence–driven analytics, and companion diagnostics
further underscore multiomics’ role in modern drug development. With healthcare
undergoing a shift toward precision medicine, expanding drug discovery and
development using multiomics services is emerging as a pivotal market driver,
promising both scientific and economic benefits.
Download Free Sample Report
Key Market Challenges
High
Cost of Multiomics Technologies
The Global Multiomics Services Market faces a
significant challenge in the form of the high cost associated with multiomics
technologies, which limits widespread adoption across both research and
clinical settings. The integration of genomics, transcriptomics, proteomics,
metabolomics, and epigenomics requires highly sophisticated platforms, advanced
sequencing technologies, and powerful computational infrastructure capable of
handling vast datasets. These resources involve substantial investment in specialized
equipment, consumables, and reagents, making multiomics studies
cost-prohibitive for many institutions and healthcare providers, especially in
resource-constrained environments. Beyond infrastructure, the costs are
compounded by the need for skilled professionals who can design experiments,
manage complex data pipelines, and perform advanced bioinformatics analysis,
often driving up operational expenses.
The expense of large-scale projects becomes even more
challenging when multiomics data are applied in clinical research or precision
medicine, as validation, regulatory compliance, and data interpretation demand
additional financial resources. High costs not only limit accessibility for
smaller research institutes and hospitals but also restrict broader patient
access to personalized diagnostic and therapeutic solutions that multiomics
could enable. This creates a divide between well-funded organizations capable
of adopting multiomics and those unable to invest at the required scale,
slowing the overall pace of market penetration. Addressing cost-related
barriers through technological innovations, more affordable sequencing methods,
and scalable cloud-based analytics will be crucial for ensuring that multiomics
services can transition from niche applications to mainstream use in global
healthcare and life sciences.
Complexity
of Data Integration and Analysis
The Global Multiomics Services Market faces a
significant challenge in managing the complexity of data integration and
analysis, which continues to act as a barrier to widespread adoption.
Multiomics involves combining data from genomics, transcriptomics, proteomics,
metabolomics, and epigenomics to generate a holistic understanding of
biological systems. Each omics layer generates massive volumes of data in
different formats and requires specialized analytical pipelines. The challenge
arises in integrating these heterogeneous datasets into a cohesive framework
that can yield meaningful biological insights. Advanced bioinformatics tools,
computational infrastructure, and domain expertise are necessary to process
this information effectively, but these resources are often limited or
expensive, creating bottlenecks in research and clinical implementation.
In many cases, organizations struggle with the
standardization of data processing protocols, which leads to inconsistencies in
results and makes cross-study comparisons difficult. Data silos across research
institutions and the lack of universally accepted integration methodologies
further complicate the problem. The requirement of highly skilled
bioinformaticians, data scientists, and systems biologists also poses a human
resource challenge, as demand often exceeds availability. These difficulties
can delay research timelines, increase operational costs, and limit the
translation of multiomics findings into practical healthcare solutions. Hence,
the complexity of data integration and analysis remains a critical hurdle for
the global market, impacting scalability and adoption.
Key Market Trends
AI and
Machine Learning in Data Integration
The integration of artificial intelligence and machine
learning into multiomics services is emerging as a transformative trend,
addressing one of the most critical challenges in the field, the complexity and
scale of multiomics datasets. Genomic, transcriptomic, proteomic, metabolomic,
and epigenomic data generate enormous volumes of information that are difficult
to analyze through conventional bioinformatics tools. AI-driven platforms are
enabling researchers to uncover hidden patterns, correlate molecular profiles,
and predict disease biomarkers with a level of precision and speed that was
previously unattainable. Machine learning models are increasingly being applied
to classify patient subgroups, identify novel therapeutic targets, and support
drug discovery pipelines. The adoption of deep learning techniques allows for
the integration of heterogeneous datasets, leading to more comprehensive
biological insights and accurate disease modeling.
Pharmaceutical and biotechnology companies are
investing in AI-powered analytics to streamline clinical trial design,
accelerate target validation, and improve patient stratification for
personalized therapies. Cloud-based AI solutions are also gaining prominence,
offering scalable infrastructure for large-scale data processing while
supporting collaboration across research institutions and healthcare
organizations. These innovations are reducing data interpretation bottlenecks,
improving reproducibility of results, and making multiomics applications more
accessible for both research and clinical use. As AI and machine learning
continue to evolve, they are expected to play a pivotal role in shaping the
future of multiomics services by enabling more efficient integration,
predictive modeling, and translation of omics data into actionable healthcare
solutions.
Cloud-Based
Data Management and Collaboration Platforms
The adoption of cloud-based data management and
collaboration platforms is emerging as a defining trend in the Global
Multiomics Services Market, driven by the exponential growth of high-throughput
sequencing and other omics technologies that generate massive and complex
datasets. Managing, storing, and analyzing this volume of data requires
infrastructure that traditional on-premises systems often cannot provide. Cloud
platforms address this challenge by offering scalable computing power, secure
storage, and advanced analytical tools that allow researchers and clinicians to
access and process multiomics data efficiently. This trend is particularly
vital as multiomics studies frequently involve integrating genomics,
transcriptomics, proteomics, epigenomics, and metabolomics datasets, which
demand seamless interoperability and real-time collaboration.
Cloud-based solutions provide an environment where
multiple stakeholders, ranging from academic institutions and research
laboratories to pharmaceutical and biotechnology companies can collaborate
across geographies, sharing insights and leveraging common datasets without the
constraints of physical infrastructure. These platforms also support compliance
with stringent regulatory frameworks by incorporating advanced data encryption
and secure access controls, which are critical when handling sensitive patient
information. The ability of cloud-based systems to integrate with artificial
intelligence and machine learning tools further enhances predictive modeling
and biomarker discovery, accelerating drug development and personalized
medicine initiatives. With growing investments from technology providers and
increasing partnerships between cloud service companies and omics research
organizations, the role of cloud-based platforms is rapidly expanding, making
them indispensable for driving efficiency, innovation, and global collaboration
in the multiomics ecosystem.
Segmental Insights
Service
Insights
Based
on the Service, Research Services emerged as the dominant segment in
the Global Multiomics Services Market in 2024. This is due to their
critical role in advancing scientific discovery and precision medicine
initiatives. Multiomics research services provide comprehensive solutions for
integrating genomics, proteomics, transcriptomics, metabolomics, and
epigenomics data, enabling a deeper understanding of disease mechanisms and
biological pathways. Academic institutions, research organizations, and
pharmaceutical companies are increasingly relying on these services to generate
insights that support biomarker discovery, therapeutic target identification,
and validation of drug efficacy. The growing demand for translational research,
coupled with the emphasis on developing novel therapies for complex diseases
such as cancer, neurodegenerative disorders, and cardiovascular conditions, has
further strengthened the position of research services.
Type
Insights
Based on the Type, Bulk Multiomics emerged as the
dominant segment in the
Global Multiomics Services Market in 2024. This dominance is due to its
wide applicability, cost efficiency, and established role in large-scale
biological studies. Bulk multiomics integrates data from genomics, proteomics,
metabolomics, and transcriptomics at the population or tissue level, providing
an aggregated view of molecular activity across samples. This approach has been
extensively used in disease biology, drug discovery, and biomarker
identification, making it the preferred choice for pharmaceutical companies,
research institutes, and academic organizations. The ability to generate robust
datasets that reveal key biological pathways and molecular interactions has
positioned bulk multiomics as a cornerstone for advancing scientific research
and therapeutic development. The dominance of bulk multiomics is also supported
by its relatively lower cost compared to single-cell or spatial multiomics,
making it more accessible for large cohort studies and longitudinal research.
Download Free Sample Report
Regional Insights
North America emerged
as the dominant region in the Global Multiomics Services Market in 2024. This is driven by strong investments in life
sciences research, advanced healthcare infrastructure, and the rapid adoption
of precision medicine initiatives. The region is home to leading biotechnology
firms, pharmaceutical companies, and research institutes that actively leverage
multiomics approaches to accelerate drug discovery, biomarker identification,
and disease diagnostics. Government funding programs, such as grants from the
National Institutes of Health (NIH) and collaborations with private sector players,
have significantly boosted the development and implementation of multiomics
technologies. The presence of cutting-edge sequencing facilities and
well-established bioinformatics capabilities has further strengthened the
region’s leadership in the market. North America’s dominance is also attributed
to its early adoption of next-generation sequencing platforms and growing
reliance on artificial intelligence and machine learning for omics data
interpretation.
Recent Developments
- In April 2025, Leica Biosystems and Bio-Techne
announced an expanded partnership to advance automated spatial multiomics
research by introducing protease-free workflows on the BOND RX instrument,
rolled out across the United States and Europe. The integration of this
technology marks a significant improvement in tissue analysis, as it minimizes
damage during sample preparation, thereby preserving tissue morphology and
molecular integrity. By streamlining workflow efficiency, the collaboration
supports the acceleration of advanced biomarker discovery and enhances the
accuracy of spatial biology studies.
- In April 2025, Source BioScience strengthened its
diagnostic services footprint in the United Kingdom by acquiring Cambridge
Clinical Laboratories. This strategic acquisition expands Source BioScience’s
testing portfolio, enabling it to deliver a wider range of specialized
diagnostic solutions with improved speed and efficiency. By combining Cambridge
Clinical Laboratories’ expertise in niche testing services with Source
BioScience’s established infrastructure, the company aims to enhance turnaround
times and meet the rising demand for high-quality diagnostic support in
oncology, infectious diseases, and genetic testing.
- In January 2025, NVIDIA announced partnerships with
leading healthcare players including IQVIA, Illumina, Mayo Clinic, and Arc
Institute to accelerate advancements in genomics, drug discovery, and
healthcare services using generative and agentic AI. By combining AI,
accelerated computing, and biological data, the company aims to transform
healthcare into a major technology-driven industry. The collaboration focuses
on developing AI agents to streamline clinical trials, AI models that leverage
biological instruments for drug discovery and digital pathology, and AI-powered
robots for surgery, monitoring, and hospital operations.
- In February 2024, Sapient, a biomarker discovery
company specializing in multi-omics data generation and analysis, launched its
high-throughput discovery proteomics services. The new offering enables
measurement of thousands of proteins in blood and tissue across diverse
biological pathways, strengthening Sapient’s biomarker discovery capabilities.
Powered by its advanced mass spectrometry-based platform, which also supports
metabolomics and lipidomics, the service is designed to address key challenges in
large-scale proteomics, including protein depth, throughput, and annotation.
Key Market Players
- Sapient
Bioanalytics, LLC
- Bio-Techne
Corporation
- CD
Genomics, Inc.
- RayBiotech,
Inc.
- Creative
Proteomics, Inc.
- Psomagen,
Inc.
- Source
BioScience Ltd.
- Persistent
Systems Ltd.
- Metware
Biotechnology Inc.
- Dalton
Bioanalytics, Inc.
|
By Service
|
By Type
|
By Application
|
By End User
|
By Region
|
- Research Services
- Data Analysis Services
|
- Single-cell Multiomics
- Bulk Multiomics
|
- Biomarker Discovery
- Drug Discovery & Development
- Synthetic Biology
- Others
|
- Academic & Research Institutes
- Pharmaceutical and Biotechnology Companies
- Others
|
- North America
- Europe
- Asia Pacific
- South America
- Middle East & Africa
|
Report Scope:
In this report, the Global Multiomics
Services Market has been segmented into the following categories, in addition
to the industry trends which have also been detailed below:
- Multiomics
Services Market,
By Service:
o
Research
Services
o
Data
Analysis Services
- Multiomics
Services Market,
By Type:
o
Single-cell
Multiomics
o
Bulk
Multiomics
- Multiomics
Services Market,
By Application:
o
Biomarker
Discovery
o
Drug
Discovery & Development
o
Synthetic
Biology
o
Others
- Multiomics
Services Market,
By End User:
o
Academic
& Research Institutes
o
Pharmaceutical
and Biotechnology Companies
o
Others
- Multiomics
Services Market, By Region:
o
North
America
§
United
States
§
Canada
§
Mexico
o
Europe
§
France
§
United
Kingdom
§
Italy
§
Germany
§
Spain
o
Asia-Pacific
§
China
§
India
§
Japan
§
Australia
§
South
Korea
o
South
America
§
Brazil
§
Argentina
§
Colombia
o
Middle
East & Africa
§
South
Africa
§
Saudi
Arabia
§
UAE
Competitive Landscape
Company
Profiles: Detailed
analysis of the major companies present in the Global Multiomics Services
Market.
Available Customizations:
Global Multiomics Services Market report with the given market data,
TechSci Research offers customizations according to a company's specific needs.
The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to
five).
Global Multiomics Services Market is an upcoming report to be released
soon. If you wish an early delivery of this report or want to confirm the date
of release, please contact us at [email protected]